摘要
目的探讨异丙托溴铵联合布地奈德、沙丁胺醇治疗老年慢性阻塞性肺疾病患者的临床效果。方法选择我院2018年12月至2020年12月收治的78例老年慢性阻塞性肺疾病患者为研究对象,遵循随机、平均原则将其分为对照组和观察组,各39例。对照组采用布地奈德和沙丁胺醇雾化吸入治疗,观察组采用异丙托溴铵联合布地奈德、沙丁胺醇雾化吸入治疗。比较两组的治疗效果。结果治疗7 d后,观察组的临床病情控制总有效率高于对照组(P<0.05)。治疗7 d后,两组的血清淀粉样蛋白A(SAA)、降钙素原(PCT)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平均较治疗前降低,且观察组低于对照组(P<0.05)。治疗7 d后,两组的神经生长因子(NGF)、碱性成纤维细胞生长因子(b-FGF)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)及基质金属蛋白酶组织抑制物-1(TIMP-1)水平均较治疗前降低,且观察组低于对照组(P<0.05)。治疗7 d后,两组的慢性阻塞性肺疾病患者自我评估测试(CAT)、改良版英国医学研究委员会呼吸困难量表(mMRC)评分均较治疗前降低,且观察组低于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论异丙托溴铵联合布地奈德、沙丁胺醇雾化吸入治疗老年慢性阻塞性肺疾病患者可有效控制病情,减轻炎症反应、气道重塑及呼吸困难症状,且未增加不良反应。
Objective To explore the clinical effect of ipratropium bromide combined with budesonide and salbutamol in the treatment of elderly patients with chronic obstructive pulmonary disease.Methods A total of 78 elderly patients with chronic obstructive pulmonary disease admitted in our hospital from December 2018 to December 2020 were selected as the research objects.The patients were divided into control group and observation group according to the principle of random and average,with 39 cases in each group.The control group was treated with budesonide and salbutamol atomization inhalation,and the observation group was treated with ipratropium bromide combined with budesonide and salbutamol atomization inhalation.The therapeutic effects of the two groups were compared.Results After 7 d of treatment,the total effective rate of clinical disease control in the observation group was higher than that in the control group(P<0.05).After 7 d of treatment,the levels of serum amyloid A(SAA),procalcitonin(PCT),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)in both groups decreased compared to those before treatment,and those of the observation group were lower than the control group(P<0.05).After 7 d of treatment,the levels of nerve growth factor(NGF),basic fibroblast growth factor(b-FGF),vascular endothelial growth factor(VEGF),matrix metalloproteinase-9(MMP-9)and tissue inhibitor of matrix metalloproteinase-1(TIMP-1)in both groups decreased compared to those before treatment,and those of the observation group were lower than the control group(P<0.05).After 7 d of treatment,the Chronic Obstructive Pulmonary Disease Assessment Test(CAT)and Modified British Medical Research Council Dyspnea Scale(mMRC)scores in both groups decreased compared to those before treatment,and those of the observation group were lower than the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The ipratropium bromide combined with budesoni
作者
李小娟
李过
张伟靖
LI Xiaojuan;LI Guo;ZHANG Weijing(the People's Hospital of Yuyang District,Yulin 719000;the First Hospital of Yulin,Yulin 719000,China)
出处
《临床医学研究与实践》
2023年第11期26-29,共4页
Clinical Research and Practice
关键词
异丙托溴铵
布地奈德
沙丁胺醇
老年患者
慢性阻塞性肺疾病
气道重塑
呼吸困难
ipratropium bromide
budesonide
salbutamol
elderly patient
chronic obstructive pulmonary disease
airway remodeling
dyspnea
